-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓Börse SIX Swiss Exchange ZürichISIN CH0012005267-
NovartisBörse SIX Swiss Exchange ZürichISIN CH0012005267 WKN: 904278Symbol NOVN.SW
-
NovartisBörse Börse MünchenEURSymbol NOTA
-
NOVARTIS AG-REGBörse Gettex System der Börse MünchenEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse DüsseldorfEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse StuttgartEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse MünchenEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse FrankfurtEURSymbol NOT
-
NovartisBörse Quotrix System der Börse DüsseldorfEURSymbol NOTA
-
NovartisBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol NOTA
-
NovartisBörse Gettex System der Börse MünchenEURSymbol NOTA
-
NOVARTIS AG-REGBörse Quotrix System der Börse DüsseldorfEURSymbol NOT
-
NovartisBörse Börse DüsseldorfEURSymbol NOTA
-
NovartisBörse Börse StuttgartEURSymbol NOTA
-
NOVARTIS AG-REGBörse Tradegate System der Deutsche Börse AG (60%)EURSymbol NOT
-
NOVARTIS AG-REGBörse Börse BerlinEURSymbol NOT
-
NOVARTIS AG-REGBörse Börse HamburgEURSymbol NOT
-
NovartisBörse NYSE New York Stock ExchangeISIN US66987V1098 WKN: 907122USDSymbol NVS
-
ISIN CH0012005267 WKN: 904278USDSymbol NOVN
-
NovartisBörse BVMF
-
NovartisBörse London Stock Exchange
-
Symbol NOTA
-
Symbol NOTA
-
CHF
-
MXN
-
USD
-
NovartisBörse Bolsa de Comercio de Buenos Aires
-
ISIN CH0012005267
WKN 904278
Symbol NOVN.SW
Börse
SIX Swiss Exchange Zürich Zeitzone: Europe/Berlin
Firmenname
Novan, Inc
Marktkapitalisierung
118.240.562.752 (+- 54%)
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
218.646.976 oder 172.940.000.000 oder 181.563.041.280
Mitarbeiter
54.012 (+- 100%)
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
23 oder 108.000 Mitarbeiter
Anzahl Aktien
2.265.008.000
KGV
17.9
EBITDA -24.745.000
Buchwert 0.02
Zahlte zuletzt am 04.03.2021 eine Dividende von 3 CHF . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Die Dividendenrendite
entsprach 3,50 % p. a.
beim aktuellen Kurs von 78,77 CHF +0,12%
Novartis underperformed den DAX um -47 % (+30 % Dividenden) vom 28.04.2014 bis 15.09.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 78,77 CHF +0,12%
Letzte Communitymeinungen
- Ein User war zuletzt bullisch
- Im Alpha-Tester Battle 2021
-
Jen
Ein User hat Novartis abonniert.
Aktionärsstruktur der Novan, Inc
Portrait der Novartis Aktie
Das Unternehmen Novan, Inc aus Schweiz beschäftigt 54.012 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Pharmazeutika, Medizinische Produkte / Medizintechnik, Biotechnologie, Pharma tätig.
Die Novartis Aktie hat inklusive der Dividendenausschüttungen seit dem 28.04.2014 eine Gesamtrendite von 49% erwirtschaftet
Das Unternehmen Novan, Inc ist in mehr als 80 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter UBS ETF (CH) SMI® gewichtet Novartis mit 16,90% im ETF.
Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Novartis Anleihen auf einen Blick.
Entdecke die 6 ETFs in denen Novan, Inc am höchsten gewichtet ist Insgesamt in 80 ETFs enthalten
Dir gefallen die Informationen zu Novartis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Novartis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Novartis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
Dir gefallen die Informationen zu Novartis?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
286 News & Informationen zur Novartis Aktie
Diabetic Nephropathy Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Analysis, Forecast Report
Top Players Covered in the Diabetic Nephropathy Market Research Report are Merck & Co., Inc., Abbott, Pfizer Inc., Siemens, Novartis AG, GENERAL ELECTRIC…
Do High-Quality International Stocks Have A Place In Your Portfolio?
Nokia (NYSE: NOK), AstraZeneca (NASDAQ: AZN) and ASML Holding (NASDAQ: ASML) are among the most popular non-U.S. developed-market stocks.
Medizintechnik: B. Braun setzt auf Datenintegration
Mit einer Plattform für die Datenintegration verbessert B. Braun Melsungen die Vernetzung mit seinen Partnern.
Brookmont Capital Management Buys ViacomCBS Inc, Honeywell International Inc, NVIDIA Corp, Sells Novartis AG, Lowe's Inc
GuruFocus Article or News written by insider and the topic is about:
Novartis, Eli Lilly and AbbVie Top 5-Year New Drug Productivity List
GuruFocus Article or News written by Barry Cohen and the topic is about: Bristol-Myers is last with just 3 novel medicines brought to market
Regenerative Medicine Market Research Report 2021-2030: Emerging Economies are Key Opportunity Areas for Market Players
/PRNewswire/ — The “Regenerative Medicine Market Research Report: By Type (Cell Therapy, Gene Therapy, Tissue Engineered Products), Application…
Regenerative Medicine Market Research Report 2021-2030: Emerging Economies are Key Opportunity Areas for Market Players
DUBLIN, July 16, 2021 /PRNewswire/ — The 'Regenerative Medicine Market Research Report: By Type (Cell Therapy, Gene Therapy, Tissue Engineered Pr…
Cathie Wood’s ARK Invest Sells Over 1.3 Million Shares of Opendoor Technologies – 24
One of Cathie Wood's Ark Invest funds sold over 1,300,000 shares of Opendoor Technologies on July 15.
Novartis to Buy AveXis in $8.7 Billion Deal
GuruFocus Article or News written by Sydnee Gatewood and the topic is about: Company strengthens its lead in the gene therapy space
7 Companies Owned By Nestlé
Nestlé deals include Gerber, Ralston Purina, Stouffer's, Atrium, Freshly, a Starbucks licensing deal, and the pending purchase of Bountiful brands.
Incyte Announces Positive Phase 3 REACH3 Study Data Published In NEJM For Ruxolitinib (Jakafi®) In Chronic Graft-Versus-Host Disease
Incyte (Nasdaq:INCY) today announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM)
Global Single Photon Emission Computed Tomography (SPECT) Market to Reach $2.5 Billion by 2026
/PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…
Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…
Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…
Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…
Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…
Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…
Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…
Non-opioid Pain Treatment Market Size to Grow at a CAGR of 16.8% from 2021 to 2030
The global non-opioid pain treatment market valued at USD 13,200.6 million in 2020, and it is projected to grow at a CAGR of 16.8 % during the forecast…
Central Nervous System Disorders Therapeutics Market |Type and Geography| Forecast and Analysis 2021-2025|Technavio
/PRNewswire/ — Technavio has been monitoring the Center Nervous System Disorder Therapeutics Market and the market size is expected to reach a value of USD 24….
Alzheimer’s Drugs Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Forecast Report
Key Prominent Players Covered in the Alzheimer’s Drugs Market Research Report Are Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company.,…
Small Cap Biotech Stocks Should Be On Your Watch List In 2021 & Here’s Why
Global Human Growth Hormone Drugs Market to Reach $4 Billion by 2026
/PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…
Europa ETF kaufen: Ist der Vanguard FTSE Developed Europe ex UK ETF ohne Großbritannien sinnvoll?
Immutep Quarterly Activities Report
Immutep entered late-stage development in the newly validated LAG-3 space
Data from 1st line NSCLC and 2nd line HNSCC presented at ASCO
Efti to be
Cathie Wood’s ARK Invest Sells for 7
Here's a look at the ARK Invest Sells for July 12, 2021.
Valuation in Geriatric Medicines Market to Reach US$ 1142.8 Bn by 2027, Use in Managing Cardiovascular Diseases Spurs Growth: TMR
/PRNewswire/ — Geriatrics care has made enormous strides over the past few decades. Rapidly aging populations notably in some emerging economies and developed…
Valuation In Geriatric Medicines Market To Reach US$ 1142.8 Bn By 2027, Use In Managing Cardiovascular Diseases Spurs Growth: TMR
ALBANY, N.Y., July 12, 2021 /PRNewswire/ — Geriatrics care has made enormous strides over the past few decades. Rapidly aging populations notably in some
Lannett : Launches Fluvastatin Sodium ER Tablets
PHILADELPHIA, July 12, 2021 /PRNewswire/ — Lannett Company, Inc. today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product…. | July 12, 2021
Late-Stage Clinical Study Readouts Biotech Investors Should Watch
Several drugmakers have important clinical trial updates on the way.
Cathie Wood’s ARK Invest Buys & Sells for 7
Here's a look at the ARK Invest buys and sells for July 9, 2021.
Active Pharmaceutical Ingredients Market Worth USD 312 Billion by 2028 at 6.2% CAGR – Report by Market Research Future (MRFR)
Active Pharmaceutical Ingredients Market Insights and Industry Analysis by Type of Synthesis (Biotech and Synthetic), By Molecules (Large Molecule and…
Cathie Wood’s ARK Invest Sells for 7
Here's a look at the ARK Invest Sells for July 7, 2021.
Global Anticoagulants Market (2021 to 2026) – by Drug Class, Route of Administration and Geography
DUBLIN, July 7, 2021 /PRNewswire/ — The 'Global Anticoagulants Market (2021-2026) by Drug Class, Route of Administration, Geography and the Impac…
Outlook On The Pulmonary Drugs Global Market To 2026 – Rising Prevalence Of Pulmonary Diseases Is Driving Growth
DUBLIN, July 7, 2021 /PRNewswire/ — The “Global Pulmonary Drugs Market (2021-2026) by Drug Class, Indication, Distribution Channel, Geography, Competitive
Malaysia Nuclear Medicines Market to Garner $70.24 Million by 2028: Allied Market Research
Rise in incidence of targeted population in Malaysia, surge in adoption of SPECT and PET scans, and increase in population of geriatric population in…
NOVARTIS AG : Goldman Sachs reaffirms its Buy rating
Already positive, the research from Goldman Sachs and its analyst Keyur Parekh still consider the stock as a Buy opportunity. The target price has been lifted and is now set at CHF 110 compared to CHF… | July 7, 2021
NOVARTIS AG : JP Morgan remains a Sell rating
The analyst from JP Morgan, Richard Vosser, maintains his advice to sell. The target price continues to be set at CHF 80. | July 6, 2021
Worldwide End Stage Renal Disease Industry To 2026 – High Focus On Technology Presents Opportunities
DUBLIN, July 5, 2021 /PRNewswire/ — The “Global End Stage Renal Disease Market (2021-2026) by Disease Type, Treatment Type, End-user, Geography, Competitive
Multicultural Organization Definition
A multicultural organization promotes diversity and inclusion among its employees and does not discriminate by race, sex, age, or any other ascribed characteristic.